会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • N-arloxyethyl-alkylamines for the treatment of depression
    • N-芳氧基乙基 - 烷基胺用于治疗抑郁症
    • US06291683B1
    • 2001-09-18
    • US09593267
    • 2000-06-13
    • Richard E. MewshawDahui Zhou
    • Richard E. MewshawDahui Zhou
    • A61K31405
    • C07D401/12C07D209/14C07D405/12
    • Compounds useful for alleviating symptoms of depression are provided which have the following formula: wherein: R1 is hydrogen, lower alkyl or aryl; R2 is hydrogen, lower alkyl, phenyl or substituted phenyl; X and Y are each, independently, hydrogen, lower alkyl, lower alkoxy, or halogen, or together combine with the carbon atoms to which they are attached to complete a cyclopentyl, cyclohexyl, phenyl, pyrrolyl, pyranyl, pyridinyl, dihydrofuranyl, furanyl, dioxanyl, oxazolyl or isoxazolyl group; Z is hydrogen, halogen or lower alkoxy; with the proviso that when X, Y or Z represent lower alkoxy, they are not present at the ortho position; W is hydrogen, halogen, lower alkyl, cyano or a trifluoromethyl group; and n is 2-5; or pharmaceutically acceptable salts thereof.
    • 提供了可用于减轻抑郁症状的化合物,其具有下式:其中:R 1是氢,低级烷基或芳基; R 2是氢,低级烷基,苯基或取代的苯基; X和Y各自独立地是氢,低级烷基 ,低级烷氧基或卤素,或与它们所连接的碳原子一起结合形成环戊基,环己基,苯基,吡咯基,吡喃基,吡啶基,二氢呋喃基,呋喃基,二恶烷基,恶唑基或异恶唑基; Z是氢,卤素 或低级烷氧基; 条件是当X,Y或Z表示低级烷氧基时,它们不存在于邻位; W是氢,卤素,低级烷基,氰基或三氟甲基; andn是2-5; 其药学上可接受的盐。
    • 5. 发明授权
    • Aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino-�2,3-e!-indol-8-ones and
derivatives
    • 氨基甲基-2,3,8,9-四氢-7H-1,4-二氧杂 - [2,3-e] - 吲哚-8-酮和衍生物
    • US5962465A
    • 1999-10-05
    • US15149
    • 1998-01-29
    • Gary P. StackRichard E. MewshawByron A. BravoYoung H. Kang
    • Gary P. StackRichard E. MewshawByron A. BravoYoung H. Kang
    • A61K31/357A61K31/40A61K31/407A61K31/4439A61P25/00A61P25/16A61P25/18A61P43/00C07D209/60C07D405/14C07D409/14C07D491/04C07D491/056C07D491/113A61K31/47
    • C07D491/04
    • The compounds of formula I: ##STR1## wherein R.sup.1 and R.sup.2 are, independently, hydrogen, alkyl, phenyl or benzyl; or R.sup.1 and R.sup.2, taken together, are benzylidene optionally substituted with R.sup.3 as defined below or alkylidene, or R.sup.1 and R.sup.2, taken together with the carbon to which they are attached, form a carbonyl moiety or a cycloalkyl group; R.sup.3 is hydrogen, hydroxy, halo, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, aralkoxy, alkanoyloxy, amino, mono- or di-alkylamino, alkanamido or alkanesulfonamido; R.sup.4 is hydrogen or alkyl; m is an integer 0, 1 or 2; n is an integer from 0 to 6, inclusive; Z is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, polycyclo-alkyl, phenyl optionally substituted with R.sup.3 as defined above, phenoxy optionally substituted with R.sup.3 as defined above, naphthyl optionally substituted with R.sup.3 as defined above or naphthyloxy optionally substituted with R.sup.3 as defined above, heteroaryl or heteroaryloxy, in which the heterocyclic ring of the heteroaryl or heteroaryloxy group is selected from thiophene, furan, pyridine, pyrazine, pyrimidine, indole, indazole, imidazole, chroman, coumarin, carbostyril, quinoline, benzisoxazole, benzoxazole, pyrazole, pyrrole, thiazole, oxazole, or isoxazole and the heterocyclic ring is optionally substituted by R.sup.3 as defined above; or a pharmaceutically acceptable salt thereof, are useful in treating disorders of the dopaminergic system.
    • 式I的化合物:其中R 1和R 2独立地是氢,烷基,苯基或苄基; 或者R 1和R 2一起是可以被如下定义的R 3取代的亚苄基或亚烷基,或者R 1和R 2与它们所连接的碳一起形成羰基部分或环烷基; R 3是氢,羟基,卤素,三氟甲基,三氟甲氧基,烷基,烷氧基,芳烷氧基,烷酰氧基,氨基,单 - 或二 - 烷基氨基,烷酰氨基或烷磺酰氨基; R4是氢或烷基; m是整数0,1或2; n为0〜6的整数,包括0和6; Z是氢,羟基,烷基,烯基,炔基,烷氧基,环烷基,多环烷基,任选被如上所定义的R 3取代的苯基,任选被如上所定义的R 3取代的苯氧基,任选被如上定义的R 3取代的萘基, 其中杂芳基或杂芳氧基的杂环选自噻吩,呋喃,吡啶,吡嗪,嘧啶,吲哚,吲唑,咪唑,苯并二氢吡喃,香豆素,喹诺酮,喹啉,苯并异恶唑, 苯并恶唑,吡唑,吡咯,噻唑,恶唑或异恶唑,杂环任选被如上定义的R 3取代; 或其药学上可接受的盐可用于治疗多巴胺能系统的病症。
    • 9. 发明授权
    • [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
    • [(吲哚-3-基) - 环烷基] -3-取代的氮杂环丁烷,用于治疗中枢神经系统疾病
    • US06245799B1
    • 2001-06-12
    • US09707146
    • 2000-11-06
    • Magda AsselinJohn W. EllingboeRichard E. Mewshaw
    • Magda AsselinJohn W. EllingboeRichard E. Mewshaw
    • A61K31404
    • C07D403/08
    • This invention provides novel compounds and pharmaceutical compositions and methods of using the compounds in the treatment of central nervous system disorders, such as anxiety and depression, the compounds having the formula I: wherein: X is N—R, O, S(O)m; m is 0 to 2; n is 0 to 4; Ar is an aryl group of 6 to 12 carbon atoms optionally substituted with 1 to 3 R3 groups, or a heteroaryl group of 4 to 10 carbon atoms optionally substituted with 1 to 3 R3 groups; R and R2 are independently H, straight chain alkyl of 1 to 6 carbon atoms, branched alkyl of 3 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, alkoxycarbonyl of 1 to 6 carbon atoms, alkylcarbonyl of 1 to 6 carbon atoms, aminocarbonyl, or alkylaminocarbonyl of 1 to 4 carbon atoms; R1 and R3 are independently H, straight chain alkyl of 1 to 4 carbon atoms, branched alkyl of 3 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, halo, alkoxy group of 1 to 4 carbon atoms, haloalkyl of 1 to 4 carbon atoms, OH, nitro, amino, sulfonyl, CN, carboxy, alkoxycarbonyl of 1 to 4 carbon atoms, alkylcarbonyl of 1 to 4 carbon atoms, aminocarbonyl, or alkylaminocarbonyl of 1 to 4 carbon atoms; or a pharmaceutically acceptable salt thereof.
    • 本发明提供了新的化合物和药物组合物和使用该化合物治疗中枢神经系统疾病如焦虑和抑郁的方法,具有式I的化合物:其中:X是N-R,O,S(O)m; m为0〜2; n为0〜4; Ar是任选被1至3个R 3基团取代的6至12个碳原子的芳基或任选被1至3个R 3基团取代的4至10个碳原子的杂芳基; R 2和R 2独立地是H,直链烷基 1至6个碳原子,3至6个碳原子的支链烷基,3至6个碳原子的环烷基,1至6个碳原子的烷氧基羰基,1至6个碳原子的烷基羰基,氨基羰基或1至4个碳原子的烷基氨基羰基; R 1和R 3独立地为H,1至4个碳原子的直链烷基,3至6个碳原子的支链烷基,3至8个碳原子的环烷基,卤素,1至4个碳原子的烷氧基,1至4个卤代烷基 碳原子,OH,硝基,氨基,磺酰基,CN,羧基,1至4个碳原子的烷氧基羰基,1至4个碳原子的烷基羰基,氨基羰基或1至4个碳原子的烷基氨基羰基;或其药学上可接受的盐。